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Abstract
Background: Data abstraction, a critical systematic review step, is time-consuming and prone to errors. Current
standards for approaches to data abstraction rest on a weak evidence base. We developed the Data Abstraction
Assistant (DAA), a novel software application designed to facilitate the abstraction process by allowing users to (1)
view study article PDFs juxtaposed to electronic data abstraction forms linked to a data abstraction system, (2)
highlight (or “pin”) the location of the text in the PDF, and (3) copy relevant text from the PDF into the form. We
describe the design of a randomized controlled trial (RCT) that compares the relative effectiveness of (A) DAA-
facilitated single abstraction plus verification by a second person, (B) traditional (non-DAA-facilitated) single
abstraction plus verification by a second person, and (C) traditional independent dual abstraction plus adjudication to
ascertain the accuracy and efficiency of abstraction.
Methods: This is an online, randomized, three-arm, crossover trial. We will enroll 24 pairs of abstractors (i.e., sample
size is 48 participants), each pair comprising one less and one more experienced abstractor. Pairs will be
randomized to abstract data from six articles, two under each of the three approaches. Abstractors will
complete pre-tested data abstraction forms using the Systematic Review Data Repository (SRDR), an online
data abstraction system. The primary outcomes are (1) proportion of data items abstracted that constitute an
error (compared with an answer key) and (2) total time taken to complete abstraction (by two abstractors in
the pair, including verification and/or adjudication).
Discussion: The DAA trial uses a practical design to test a novel software application as a tool to help
improve the accuracy and efficiency of the data abstraction process during systematic reviews. Findings from
the DAA trial will provide much-needed evidence to strengthen current recommendations for data abstraction
approaches.
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Background
Systematic reviews (“reviews”) are comparative effective-
ness research studies that use explicit methods to identify,
appraise, and synthesize the research evidence addressing
a given research question [1]. The steps in completing a
review include formulating the research question, finding
and collecting data from individual studies, and synthesi-
zing the evidence [2]. The validity of the review findings is
contingent upon accurate and complete data collection
from journal articles reporting results of relevant studies
(“articles”), a process known as data abstraction (also known
as data extraction).
As a predominantly manual process, data abstraction
is inefficient, being both labor-intensive and error-prone.
Errors during abstraction are common and have been well
documented in the literature [3–6]. One study estimated
that the error rate, defined as “any small discrepancy from
the reference standard,” was approximately 30% for single
abstraction, regardless of the level of abstractor experience
[6]. Our pilot data showed that less experienced abstrac-
tors made more errors across all types of research ques-
tions, and errors were highest for numerical results [7].
Abstraction errors occur when abstractors either omit
from the abstraction information that is present in the
article or when information is abstracted incorrectly. When
Gøtzsche and colleagues examined 27 meta-analyses
(i.e., statistical analyses of results from included studies in
systematic reviews) published in 2004 across a range of
topics, they found multiple errors in 37% of meta-analyses
[4]. In another study, Jones and colleagues documented
abstraction errors in 20/42 reviews (48%); in all cases,
the errors changed the summary meta-analytic results,
although none changed the review conclusions [5].
Currently recommended approaches to reducing errors
in data abstraction fall into two categories: (1) abstraction
by one person followed by checking of the abstraction by
a second person (“single abstraction plus verification”)
and (2) independent abstraction by two persons followed
by resolution of any discrepancies (“independent dual
abstraction plus adjudication”). The former approach also
sometimes concludes with adjudication between the two
abstractors. Buscemi and colleagues showed that single
abstraction plus verification results in approximately
20% more errors than independent dual abstraction plus
adjudication, but the latter approach takes approximately
50% longer [3].
Because only one study [3] has examined the tradeoffs
between single abstraction plus verification and inde-
pendent dual abstraction plus adjudication and that study
focused on a single review topic with only four abstrac-
tors, current standards for data abstraction rest on a weak
evidence base. Major sponsors and producers of reviews
(e.g., Agency for Healthcare Research and Quality Evidence-
based Practice Centers (AHRQ EPCs), Cochrane, Centre for
Research and Dissemination (CRD)) and organizations that
develop methodology standards for reviews (e.g., AHRQ,
Cochrane, Institute of Medicine (IOM)) are inconsistent in
their recommendations for approaches to reduce errors in
abstraction [1, 2, 8–10]. Because “so little is known about
how best to optimize accuracy and efficiency” [1], the IOM
Committee stopped short of recommending independent
dual abstraction for all data elements. Instead, the IOM rec-
ommended: “at minimum, use two or more researchers,
working independently, to extract quantitative and other
critical data from each study” [1]. Thus, although the IOM
recommended independent dual abstraction for “critical
data,” an important gap in our current methodological
understanding of data abstraction remains. The recom-
mendation for “critical data” could represent unnecessary
work or, conversely, the IOM’s implicit recommendation
that a single person could abstract non-critical data could
represent an opportunity for error.
Computer-aided abstraction could potentially make the
abstraction process more efficient and more accurate by
facilitating the location and storage of key information in
articles. With funding from the Patient Centered Out-
comes Research Institute (PCORI), we developed the
Data Abstraction Assistant (DAA), a novel software appli-
cation designed to facilitate tracking the location of ab-
stracted information in articles and to reduce errors during
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abstraction. DAA facilitates abstraction by allowing users
to (1) view article PDFs juxtaposed to electronic data ab-
straction forms in data abstraction systems, (2) highlight
(or “pin”) the location of text in the PDF, and (3) copy text
automatically from the PDF into the form.
We are conducting a randomized controlled trial
(RCT) to compare the relative effectiveness of (A) DAA-
facilitated single abstraction plus verification, (B) trad-
itional (non-DAA-facilitated) single abstraction plus veri-
fication, and (C) traditional independent dual abstraction
plus adjudication on the accuracy and efficiency of ab-
straction. The objective of this manuscript is to describe
the design of our RCT adhering to the Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT)
evidence-based guideline for reporting protocols of RCTs
[11] (Additional file 1). Our searches of PubMed and The
Cochrane Library up to August 26, 2016, did not identify
any RCT or systematic review of RCTs that have compared
the accuracy and efficiency of various data abstraction
approaches.
Methods
Study design and setting
We have designed this study as a randomized, three-arm,
crossover trial. The trial flowchart is presented in Fig. 1.
This trial will be conducted entirely online. However,
during verification of abstracted data or adjudication of
discrepancies, participants (abstractors) in a pair will have
the option to communicate with each other using any
preferred mode of communication (e.g., video call, phone
call, in-person meeting).
Study population
The intended study population is individuals, including
researchers, patients, clinicians, and methodologists, who
have previously participated in data abstraction for sys-
tematic reviews, without restriction on the number, types,
or topics of reviews.
Eligibility criteria
The trial will only include individuals who meet all the
following criteria:
 At least 20 years of age
 Self-reported proficiency with reading scientific
articles in English
 Completed abstraction for at least one journal
article for a systematic review in any field
 Provided informed consent
Recruitment
For this trial, we will use the Systematic Review Data
Repository (SRDR) as the data abstraction system. SRDR,
maintained by the Brown University EPC (http://
srdr.ahrq.gov), is state-of-the-art, open-source, open-access,
and available free of charge to anyone conducting a review
[12, 13]. We will utilize four strategies to identify and re-
cruit potential abstractors: (1) emails to students who have
registered for at least one course in systematic review
methods through Johns Hopkins Bloomberg School of Pub-
lic Health (JHBSPH) and Brown University; (2) emails to
faculty and staff at Johns Hopkins and Brown EPCs; (3) ad-
vertising on the SRDR website; and (4) advertising through
patient organizations such as Consumers United for
Evidence-based Healthcare (CUE) and Cochrane Consumer
Network (CCNet). CUE is a US-based coalition of health
and patient advocacy organizations committed to empow-
ering patients to make the best use of evidence-based
healthcare (http://us.cochrane.org/CUE). CCNet’s primary
role is to get patients around the world involved in the pro-
duction of Cochrane reviews (http://consumers.cochra-
ne.org). All potentially eligible abstractors are directed to
the DAA Trial Data Abstractor Enrollment website
(“Enrollment website”), the informational page for the
trial (http://srdr.ahrq.gov/daa/info).
Fig. 1 Flow of participants during the trial
Saldanha et al. Systematic Reviews  (2016) 5:196 Page 3 of 11
Participant enrollment, training, and pairing
To mimic how individuals are often paired for data ab-
straction in real-world reviews, we will form pairs of ab-
stractors consisting of one less experienced abstractor
and one more experienced abstractor. The Enrollment
website will ask participants to answer questions related
to their eligibility and level of experience with abstrac-
tion for reviews. Based on the results of a pilot study
(Additional file 2), we determined that the number of
published reviews authored, dichotomized at fewer than
3 versus 3 or more, was best able to classify abstractors
as “less” or “more” experienced with abstraction,
respectively.
Once an abstractor is deemed to have met all eligibility
criteria for the trial and has provided information regar-
ding experience with abstraction, the Enrollment website
will notify the abstractor that s/he is eligible for partici-
pation and, upon the click of a button, will direct the
participant to the DAA Trial Informed Consent website
(“Consent website”) (http://srdr.ahrq.gov/daa/consent). The
Consent website will automatically notify the Project
Director regarding the names and email addresses of
abstractors who have successfully provided informed
consent.
Abstractors will be required to complete training in
using SRDR and DAA before being paired and random-
ized. Once an abstractor has completed training, the Pro-
ject Director pairs the abstractor with the next available
abstractor, in chronological order, who has complemen-
tary abstraction experience (i.e., each pair will include one
less experienced and one more experienced abstractor).
Randomization of pairs of abstractors
Abstractors will be randomized as pairs. Each pair will
complete abstraction for six articles, two under each of
the three approaches (A =DAA-facilitated single abstrac-
tion plus verification; B = traditional [non-DAA-facilitated]
single abstraction plus verification; and C = traditional in-
dependent dual abstraction plus adjudication). This is to
reduce possible contamination from the learning process
and for ease of coordination. To maximize efficiency, we
will use a crossover design such that each pair of abstrac-
tors will implement all three approaches being evaluated,
with the intent of estimating differences within pairs. The
six possible sequences are AABBCC, AACCBB, BBCCAA,
BBAACC, CCAABB, and CCBBAA. Table 1 lays out the
assignment of 24 abstractor pairs to sequences (n = 6) and
to reviews (n = 4). For further explanation of sample size
calculation and review selection, see sections titled “Sample
size and power calculation” and “Identification of studies
and outcomes for abstraction during the trial”, respectively.
We will randomly assign each consecutive pair of abstrac-
tors to a “slot” (row in Table 1). The Senior Statistician
will use the R statistical environment to generate the
random order from 1 to 24. For example, if the first ran-
dom number is 17, the first pair will be assigned to “pair
17”, and will abstract data from articles 31 to 36 accord-
ing to sequence BBAACC, as shown in Table 1.
The Project Director will release two articles at a time.
To maintain allocation concealment, we will keep the
Project Director, who is responsible for pairing abstrac-
tors and communicating the randomized sequence to the
pair, unaware of the next slot assigned. For this reason,
the Senior Statistician alone will have access to the random
order. For each pair to be randomized, the Project Director
will contact and receive from the Senior Statistician the
randomized slot to which the pair will be assigned.
Study arms (abstraction approaches)
Approach A—DAA-facilitated single abstraction plus
verification
In Approach A, which uses DAA, the less experienced
abstractor in a pair will complete the abstraction form
first, followed by the more experienced abstractor who
will verify the information abstracted by her/his less ex-
perienced partner. The less experienced abstractor will
complete abstraction for the two assigned articles using
DAA and the abstraction form in SRDR by placing a pin
identifying each location of the PDF text supporting the
answer to every question on the abstraction form. The
software allows multiple locations of the PDF text to be
pinned for a given question. Once the initial abstraction
is completed, the more experienced abstractor will be
given access the abstracted data for the two articles in
SRDR, together with the pinned locations on the PDFs.
The more experienced abstractor can change any of the
less experienced abstractor’s responses as s/he considers
appropriate (verification) and, if desired, request discus-
sion with the less experienced abstractor (data adjudica-
tion). Once the more experienced abstractor has verified
the data abstracted for an article (with or without dis-
cussion with the less experienced abstractor), abstraction
for that article will be considered complete.
Approach B—Traditional single abstraction plus verification
Approach B does not use DAA. As in Approach A, the
less experienced abstractor in a pair will complete the
abstraction form first (without using DAA), followed by
the more experienced abstractor who will verify the infor-
mation abstracted by her/his less experienced partner.
The less experienced abstractor in a pair will complete
abstraction for the assigned articles using the abstraction
form in SRDR. Once the abstraction by the less expe-
rienced abstractor is completed, the more experienced
abstractor will be given access the abstracted data for the
two articles in SRDR. The more experienced abstractor
can change any of the less experienced abstractor’s re-
sponses as s/he considers appropriate (verification) and, if
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desired, request discussion with the less experienced
abstractor to adjudicate the data (data adjudication). As in
Approach A, once the more experienced abstractor has
verified the abstracted data for an article (with or without
discussion with the less experienced abstractor), abstrac-
tion for that article is considered complete.
Approach C—Traditional independent dual abstraction plus
adjudication
Approach C, which also does not use DAA, involves
two main steps. In the first step, the two abstractors in a
pair each will abstract data independently for the two
assigned articles using the abstraction form in SRDR.
The two abstractors will inform each other that they
have completed their independent abstractions and will
develop a plan for adjudication (e.g., video call, phone call,
in-person meeting). In the second step, the abstractors
will compare their abstractions and address any discrep-
ancies in the abstracted data for the two articles (data
adjudication). Once the two abstractors arrive at consen-
sus on all abstracted data for a given article, abstraction
for that article is considered complete. As appropriate,
Table 1 Assignment of 24 pairs of abstractors to 6 sequences and to 48 articles
Random sequence
Article 1 Article 2 Article 3 Article 4 Article 5 Article 6 Articles selected from systematic review #1
Pair 1 A A B B C C Sequence 1
Pair 2 B B C C A A Sequence 2
Pair 3 C C A A B B Sequence 3
Article 7 Article 8 Article 9 Article 10 Article 11 Article 12
Pair 4 A A C C B B Sequence 4
Pair 5 B B A A C C Sequence 5
Pair 6 C C B B A A Sequence 6
Article 13 Article 14 Article 15 Article 16 Article 17 Article 18 Articles selected from systematic review #2
Pair 7 A A B B C C Sequence 1
Pair 8 B B C C A A Sequence 2
Pair 9 C C A A B B Sequence 3
Article 19 Article 20 Article 21 Article 22 Article 23 Article 24
Pair 10 A A C C B B Sequence 4
Pair 11 B B A A C C Sequence 5
Pair 12 C C B B A A Sequence 6
Article 25 Article 26 Article 27 Article 28 Article 29 Article 30 Articles selected from systematic review #3
Pair 13 A A B B C C Sequence 1
Pair 14 B B C C A A Sequence 2
Pair 15 C C A A B B Sequence 3
Article 31 Article 32 Article 33 Article 34 Article 35 Article 36
Pair 16 A A C C B B Sequence 4
Pair 17 B B A A C C Sequence 5
Pair 18 C C B B A A Sequence 6
Article 37 Article 38 Article 39 Article 40 Article 41 Article 42 Articles selected from systematic review #4
Pair 19 A A B B C C Sequence 1
Pair 20 B B C C A A Sequence 2
Pair 21 C C A A B B Sequence 3
Article 43 Article 44 Article 45 Article 46 Article 47 Article 48
Pair 22 A A C C B B Sequence 4
Pair 23 B B A A C C Sequence 5
Pair 24 C C B B A A Sequence 6
A, B, and C denote three different approaches for data abstraction; see the section “Study arms (Abstraction approaches)”. Random sequence is the permuted
arrangement of three approaches for data abstraction. For example, sequence 1 indicates data abstractors will collect data from 6 unique articles using AABBCC
approaches respectively
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both abstractors will edit their own incorrect answers. We
will not allow a third abstractor to resolve discrepancies.
Masking
It is not feasible to mask abstractors or the Project
Director because the abstractors need to be aware of the
abstraction approach in order to abstract data, and the
Project Director needs to be aware of the sequence of
assigned approaches to allocate articles and follow abstrac-
tors through the trial. The data analysts will use computer
programs, such as the R statistical environment, to detect
errors (a step that does not involve subjective judgment),
and will not be masked.
Follow-up and retention of participants
To maximize retention, the Project Director will main-
tain regular email contact with each abstractor (or pair
of abstractors, as appropriate) throughout the trial. Follow-
ing are the scheduled junctures for email contact: after
screening and consent, once DAA and SRDR trainings
are completed, after randomization, and after abstraction
under each approach (two articles) is completed. Abstrac-
tors will be followed throughout the trial unless consent
is withdrawn. In instances where an abstractor or pair of
abstractors does not complete abstraction for the assigned
articles, we will make every effort to encourage comple-
tion of abstraction. If abstraction is not completed after
five weekly email reminders, or if consent is withdrawn,
we will replace the abstractor with a previously not en-
rolled abstractor with the same level of abstraction experi-
ence, or replace both abstractors in the pair, as needed,
so that the remaining abstraction is completed.
We will provide each abstractor US $250 as compen-
sation for participation in the trial. Compensation will
be provided only once abstraction for all six articles has
been completed (i.e., no partial/interim payment).
Identification of studies and outcomes for abstraction
during the trial
We have identified 48 journal articles from four reviews
reporting results of RCTs (12 articles per review), and
these are the articles that will be abstracted from during
the trial. We identified the reviews by searching MED-
LINE and the Cochrane Database of Systematic Reviews
for a range of clinical topic areas. To ensure that the
reviews and the outcomes are relevant to patients, our
consumer co-investigators (SAW, EJW, and Ms. Vernal
Branch) were involved in the selection of reviews and
outcomes. In cases where a review includes more than 12
articles, we selected 12 articles that reported the most
number of outcomes. We have included one article for
each trial (i.e., not multiple publications, conference ab-
stracts, or data from trial registries).
The reviews chosen are (1) multi-factorial interventions
to prevent falls in older adults [14]; (2) proprotein con-
vertase subtilisin/kexin type 9 (PCSK-9) antibodies for
adults with hypercholesterolemia [15]; (3) interventions
to promote physical activity in cancer survivors [16]; and
(4) omega-3 fatty acids for adults with depression [17].
Data collection, management, and monitoring
All data during the trial will be collected via websites,
SRDR (the data abstraction system), and DAA (the docu-
ment management system). We have developed and pilot
tested a separate data abstraction form compatible with
SRDR for each of the four reviews (forms available upon
request). We want the results of our trial to be broadly
applicable across a wide range of review topics, and thus,
the forms include recommended common data elements
(Table 2) [13, 18]. In keeping with best practices of form
development [13], each form comprises predominantly
pre-populated multiple-choice or numerical entry data
items. We have organized the data elements into separate
“tabs” in SRDR: Design Tab (study design, risk of bias),
Baseline Tab (characteristics of participants by study arm
at baseline), Outcomes Tab (list of outcomes reported in
the article), and Results Tab (quantitative results data for
the outcomes). Table 2 lists the various data elements that
are contained in each tab, framed as answerable ques-
tions. Note that some data elements include multiple data
items. The total number of data items varies between arti-
cles, depending upon the review topic, number of out-
comes, and the amount of information available in each
article. The form has a median of 121 multiple-choice or
numerical entry data items (interquartile range 102 to 150,
range 71 to 176).
The DAA trial does not include stopping rules or a
Data Safety and Monitoring Board because the trial
does not evaluate the safety or effectiveness of an
intervention on health outcomes. We do not expect
any adverse events as a result of abstracting data dur-
ing this trial.
Outcomes
The two primary outcomes for our trial are proportion
of data items abstracted that constitute an error (hereafter
referred to as “error rates” for simplicity) and the time
taken to complete abstraction (by both abstractors, in-
cluding verification/adjudication). To determine errors
for Approaches A and B, we will compare the verified
data to data independently abstracted and adjudicated
by two investigators with extensive abstraction experi-
ence (IJS and TL), which will be considered the “an-
swer key”. In Approach C, both abstractors edit their
own abstracted data during adjudication. To determine
errors for Approach C, we will use the edited data
from the more experienced abstractor. We will do this
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by using a computer program that automatically com-
pares the selected/entered value of a given data item
to the answer key value for that data item. An error is
defined as any discrepancy or difference between an
entry for a data item and the answer key value for
that data item. We are interested in abstraction errors
resulting from omission or incorrect abstraction. If
participants abstract more data items than are in the
answer key, the additional data items will not be con-
sidered as errors.
The total time taken to complete abstraction for a
given article is defined as the sum of the time taken
for initial abstraction(s) plus subsequent verification/ad-
judication. To measure time, we will use three strategies.
First, the study data abstraction system (i.e., SRDR) will
automatically record when each abstractor logs in and
out of the system, including the time spent on each tab.
It is possible that this time overestimates the true time
spent on the tab if the abstractor steps away from the
computer. Second, as part of the Design Tab of the ab-
straction form in SRDR, we will ask abstractors to record
the self-timed duration (in minutes) that was spent
abstracting data for the Design Tab. Third, we will ask
each abstractor to record the time spent (in minutes)
on each step of data abstraction for each article: initial
abstraction, verification, and adjudication, recorded using
an online survey tool (Qualtrics®). We will use the auto-
matically recorded timestamps to calculate time when-
ever possible, but will corroborate these data with the
latter two manual strategies to assess the accuracy of our
assessment of time.
To explore the impact of errors on results of meta-
analyses, we also will conduct an exploratory descriptive
analysis of differences among the meta-analytic estimates
and 95% confidence intervals based on data derived from
Approaches A, B, and C compared with those using the
answer keys.
Table 2 Data elements by tab in each abstraction form used
in the trial
Tab Data element
Design Study eligibility criteria
Number of study centers
Region of study participant recruitment
Start year of study participant recruitment
End year of study participant recruitment
End year of randomized study participant follow-up
Length of planned (or stated) randomized study
participant follow-up
Report of a study sample size/power calculation
Report of conduct of an intention-to-treat analysis
Presence of a participant flow diagram in the article
Study method to generate the random sequence
Risk of bias related to random sequence generation
Study method to conceal the random allocation sequence
Risk of bias related to concealment of the random
allocation sequence
Masking (or blinding) of study participants to treatment
assigned
Masking (or blinding) of healthcare providers to treatment
assigned
Masking (or blinding) of outcome assessors to treatment
assigned
Report of “single,” “double,” or “triple” masking without
clarification
Report of absence of any masking during the study
Sources of monetary or material support for the study
Financial relationships for any author of the study article
Total number of randomized study arms (or groups)
Number of study participants randomized, by group (or arm)
Number of study participants followed up, by group (or arm)
Whether reasons to follow up were similar between the
groups (or arms)
How much time the abstractor spent abstracting data
for the Design Tab
Baseline Sample size at baseline, by group (or arm)
Age at baseline, by group (arm)
Sex at baseline, by group (arm)
Other baseline characteristics as appropriate
(e.g., body mass index), by group (arm)
Outcomes Each outcome from a pre-defined list of outcomes with
time-points specific to articles from each review
Results For each dichotomous outcome at the relevant time-point:
Number of participants analyzed, by group (arm)
Number of participants with the outcome, by group (arm)
Percentage of participants with the outcome, by group (arm)
Measure of association (e.g., relative risk, odds ratio),
by between arm comparison
Table 2 Data elements by tab in each abstraction form used
in the trial (Continued)
95% CI for the measure of association, by between
arm comparison
P-value for the measure of association, by between
arm comparison
For each continuous outcome at the relevant time-point:
Number of participants analyzed, by group (arm)
Mean of outcome, by group (arm)
Standard deviation of outcome, by group (arm)
Mean difference, by between arm comparison
95% CI for the mean difference, by between arm comparison
P value for the mean difference, by between arm comparison
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Statistical methods
Statistical analysis—overview
All analyses will be conducted according to the intention-to-
treat principle. We will document any protocol deviations
and violations. We will compute summary error rates and
time statistics for each approach, abstractor pair, review, and
article, by type of question (questions in the Design Tab,
Baseline Tab, or the Outcomes and Results Tabs). We expect
each of our primary outcomes (error rate and time) to vary
by six factors; we have included these factors as covariates
in the statistical model for analyzing each of the primary
outcomes. These factors include question type (design,
baseline, results), abstractor pair (1 to 24), abstraction
sequence (1 to 6), abstraction approach (A, B, C), article
(1 to 48), and review from which articles were obtained
(1 to 4). We will define errors for each data item as a binary
variable (correct/incorrect) and time as a continuous vari-
able. We will analyze error rates using logistic regression
and time using linear regression. Each outcome will be
analyzed in terms of the six factors using a mixed effects
regression model.
Statistical analysis—technical details
For modeling error rates, let phijklmn be the probability
of an error for the hth item of the ith question type
abstracted by the jth abstractor pair following the kth
abstraction sequence under the lth abstraction approach
from the mth article obtained from the nth review. Then,
the logistic regression model is
logit phijklmn ¼ a þ qi þ bl þ gk þ dn þ hj kð Þ
þ zm nð Þ þ bqð Þli þ bgð Þlk
þ bdð Þln þ …
where “…” indicates additional interaction terms one may
wish to add. Question type (qi), abstraction approach (bl),
and abstraction sequence (gk) are fixed factors; abstractor
pair (hj(k)), review (dn), and article (zm(n)) are random
factors. The key term of interest is bl, representing the
main effect of the abstraction approach. The interaction
terms (bq)li, (bg)lk, and (bd)ln in the model examine
whether differences between the abstraction approaches
vary with type of questions asked on the abstraction form
(since some questions might be easier to answer than
others), abstraction sequence (which might indicate a
learning effect or, more formally, a carry-over effect), and
review (which might indicate a level of difficulty effect),
respectively. We will check whether other factors explain
differences among the abstractors (e.g., level of experience)
or among the articles (e.g., better reporting). Each random
effect is assumed to follow a normal distribution centered
at zero with its own variance component. Correlations
among items taken from the same article, for example,
are explained by the common variance components. The
model for the continuous time outcome has a similar struc-
ture, but utilizes a linear regression modeling the mean
time with normally distributed errors. We will examine
both error rates and time adjusting for type of question on
the abstraction form and will also examine error rates and
time for each type of question separately. We will compare
automatically recorded and self-reported times, and analyze
each separately.
Subgroup analyses
We will conduct exploratory subgroup analyses to exa-
mine whether the differences between the three abstrac-
tion approaches vary by question type, abstractor pair,
abstraction sequence, article, and review, as specified in
the statistical model (see the “Statistical analysis—technical
details” section).
Missing data and sensitivity analysis
We anticipate that missing data may occur if abstractors
do not finish all six articles assigned. We will make every
effort to retain all abstractors and encourage complete
data collection through (1) describing sufficient detail
about the trial, problems caused by missing data, and the
need for commitment to the trial as part of the consent
process before enrollment; (2) maintaining frequent con-
tact and sending reminders to abstractors; and (3) com-
pensating abstractors US $250 for their time once they
have completed all assignments. We will ask and report
reasons for those who discontinue some or all types of
participation.
In handling missing data items, we will compare the
characteristics of the missing and non-missing items
to determine the nature of the missing data mechanism.
If data appear to be missing at random, inference can be
drawn based on the observed data mixed model likeli-
hood, as the predictor factors are all part of the design
and therefore will be known. If the missing at random
assumption appears invalid, we will conduct sensitivity
analyses to assess robustness of findings to different miss-
ing not at random scenarios.
Sample size and power calculation
The purpose of our trial is to determine whether (1) use
of DAA (Approach A) improves accuracy (i.e., reduces
error rates) compared with Approach B, and maintains
the accuracy of the usual Approach C; and (2) use of
DAA improves efficiency (i.e., reduces abstraction time)
compared with Approaches B and C. The adjudicated
abstractions of the experienced study investigators (IJS
and TL) will be used as the answer key for comparison.
The design in Table 1 includes factors related to the
abstractor pair, abstraction sequence, article, and review.
For determining necessary sample sizes, we make the
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simplifying assumption that the error rates and abstrac-
tion time per article will not depend on pair, sequence,
or review. We consider this trial as having a crossover
design in which each of the 48 articles is abstracted three
times, once under each abstraction approach.
In our pilot study, we found that the proportion of
items incorrectly abstracted by inexperienced abstractors
was 24% [7]. If an experienced reviewer caught and cor-
rected half of these errors, the error rate would be re-
duced to 12%; this is what we used in sample size and
power calculations for Approach B. We assume that
DAA-facilitated single abstraction plus verification (Ap-
proach A) would reduce the error rate relative to trad-
itional single abstraction plus verification (Approach B),
but perhaps not relative to independent dual abstraction
plus adjudication (Approach C). Given the expected
error rate, we want to be able to estimate the differ-
ence in error rate to within 1 or 2% in order to be able to
determine which approach is meaningfully more accurate.
For example, with an error rate of 12% for Approach B,
we will be able to detect a statistically significant differ-
ence between Approaches A and B if Approach A’s error
is less than 10%.
Using the error rate as the outcome for calculating
sample size, we would expect a standard deviation for a
100-item form to be about 3% (exact if the proportion
were 9%). The standard error of the difference is then
σ(1 − ρ)/N, where σ is the within-unit standard deviation,
N is the number of units (articles) receiving each sequence
of crossovers (Approaches A, B, and C), and ρ is the
correlation between two measurements on the same unit.
The standard error for the difference in a crossover trial
when comparing two approaches with 24 units each
receiving each approach in one of two sequences, given a
standard deviation per unit of 3%, ranges from 0.125%,
when ρ = 0, to 0%, when ρ = 1, decreasing linearly. Thus,
even if measurements are uncorrelated (i.e., ρ = 0), our
design would be able to detect a very small difference
between error rates.
Likewise, we might assume that Approach A would
reduce the total time needed to abstract data relative to
Approaches B and C, and we would want to estimate this
within a few minutes in order to determine meaningful
differences in efficiency. The same calculation shows that
even with independent measurements, the standard error
of the difference between the average times for two diffe-
rent approaches would be no more than σ/24, which
would be less than 2 min for σ as large as 48 min (48 min
is much longer than we would expect for the amount of
data to be abstracted and the length of the articles).
Confidentiality
We will not share trial data until the trial is completed
and primary analyses are done. There are no personally
identifying markers for participants in the data we col-
lect. A file linking participant names with the assigned
abstraction sequence will be accessible only to the Pro-
ject Director and saved on a password-protected server
maintained by JHBSPH. The server is backed up daily.
We will archive trial documentation and electronic data
files at the end of the trial and will retain them for at least
10 years. Because data abstracted in SRDR are associated
with the abstractor’s name, we do not plan on allowing
open access to the abstracted data in SRDR. However,
upon request, we can make the exported de-identified
abstracted data available after the trial.
Publications and dissemination
All investigators will collaborate to disseminate trial re-
sults through manuscripts and presentations at scientific
meetings. Authorship and roles in preparation of the
manuscripts will be decided ahead of time and agreed by
all concerned. PCORI, the funder of this trial, will con-
vene an independent team to peer review the final report
of the project and will post the finalized report on the
PCORI website.
Discussion
Current approaches to data abstraction have resulted in
a large resource burden on those conducting systematic
reviews; however, efforts to reduce the burden may lead to
errors in abstraction. These errors could lead to inaccurate
conclusions derived in reviews and, consequently, health-
care decisions that are based on faulty evidence summa-
ries. The very foundation of evidence-based healthcare is
challenged when one of its three underlying tenets
(best-available research evidence, clinician expertise, and
patient values [19]) is compromised.
Challenges in designing the trial
The first challenge in designing this trial was to identify
four reviews from which we could meet our target of
identifying 12 appropriate RCTs each. Many of the re-
views we selected initially could not be used because the
outcomes were poorly defined in the reviews and, in
some instances, meta-analyses in the reviews combined
data from RCTs inappropriately. Ultimately, after ruling
out various topics, we identified four suitable topics and
reviews.
The second challenge was deriving the answer keys
for all 48 articles. Two experienced abstractors on our in-
vestigator team (IJS and TL) abstracted data from all 48
articles. However, to be able to truly evaluate abstraction
“errors” by abstractors during the trial, we needed to de-
velop instructions and unambiguous language to clearly
articulate every question and every answer option on
every abstraction form for use during the trial. Ambigu-
ous articulation of these entities on our forms could have
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led to information bias in a primary outcome of the DAA
trial if the abstraction errors resulted not from omission
or incorrect abstraction, but rather an abstractor’s misun-
derstanding of the abstraction requested.
To reduce the abstraction process learning curve, we
are restricting the trial to individuals with at least some
experience with data abstraction for systematic reviews.
Another limitation is that, unlike many real-world reviews,
we are not allowing resolution of abstraction discrepancies
by a third abstractor.
Strengths of the trial design
This trial has many strengths. First, it tests a novel soft-
ware application (DAA) designed to make the data ab-
straction process more accurate and efficient. In addition,
used in conjunction with a data abstraction system such
as SRDR, DAA would maintain an annotated version of
the data abstracted for easy access when the same or
another systematic review team updates the review at a
later date. Second, using a rigorous and efficient cross-
over design with random allocation and allocation con-
cealment, this trial tests the effectiveness of the software
application vis-à-vis two currently recommended best
practice approaches to abstraction. Third, we are collab-
orating with patient/consumer co-investigators as the trial
moves forward, in designing the trial and identifying the
review topics, study articles, and outcomes for use during
abstraction. Finally, the generalizability of the trial is likely
to be high because of the broad eligibility criteria for
abstractors from multiple locations with various types
of background and levels of experience with abstraction
during reviews.
In summary, current standards for data abstraction, a
key step during systematic reviews, rest on a weak evi-
dence base. Our trial represents a potentially substantial
step forward in the quest to reduce errors in data abstrac-
tion. The trial will rigorously evaluate whether a novel
software application (DAA) could help the systematic re-
view community efficiently use scarce research resources.
Because systematic reviews are a key component of com-
parative effectiveness research, our results could help
improve patient care by reducing errors in the synthesis
of research evidence that informs that care.
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